TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

TRAIL induces apoptosis in cancer cells whilst sparing normal tissues. Despite promising pre-clinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene
Hauptverfasser: Tuthill, Mark H, Montinaro, Antonella, Zinngrebe, Julia, Prieske, Katharina, Draber, Peter, Prieske, Stefan, Newsom-Davis, Tom, von Karstedt, Silvia, Graves, Jonathan, Walczak, Henning
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4240732/
https://ncbi.nlm.nih.gov/pubmed/24909167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2014.156
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge